TP53 and ovarian carcinoma: Our data provide the first evidence that ovarian cancer patients with oncomorphic TP53 mutations have worse clinical outcomes compared to patients with unclassified TP53 mutations, including a shorter PFS and a 60% greater risk of recurrence.